POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for myelofibrosis patients with severe anemia
Disease control OngoingThis study tests a new drug (INCB000928) given alone or with another drug (ruxolitinib) in 84 people with myelofibrosis who have anemia. The goal is to find a safe dose that can raise red blood cell levels and reduce the need for blood transfusions. The study is in early phases (…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 17, 2026 02:43 UTC
-
New combo aims to shrink spleens and ease symptoms in rare blood cancer
Disease control OngoingThis study tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not had prior JAK inhibitor treatment will participate. The main goal is to see if…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 02:42 UTC
-
New hope for rare bone marrow cancer patients with dangerous low platelets
Disease control OngoingThis study tests a drug called pacritinib against standard treatments in about 400 people with myelofibrosis, a type of bone marrow cancer, who also have very low platelet counts (below 50,000). The goal is to see if pacritinib can shrink the spleen and improve symptoms like bell…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated May 17, 2026 02:24 UTC
-
Can a drug calm the chaos of myelofibrosis?
Disease control OngoingThis study tests a drug called canakinumab in people with myelofibrosis, a serious bone marrow disorder. The goal is to see if it can improve symptoms, anemia, or reduce spleen size. About 14 adults will receive injections every three weeks for 24 weeks. The study is currently ac…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 11, 2026 20:46 UTC